Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma

Lisa H Treat, Nathan McDannold, Yongzhi Zhang, Natalia Vykhodtseva, Kullervo Hynynen, Lisa H Treat, Nathan McDannold, Yongzhi Zhang, Natalia Vykhodtseva, Kullervo Hynynen

Abstract

The blood-brain barrier (BBB) inhibits the entry of the majority of chemotherapeutic agents into the brain. Previous studies have illustrated the feasibility of drug delivery across the BBB using focused ultrasound (FUS) and microbubbles. Here, we investigated the effect of FUS-enhanced delivery of doxorubicin on survival in rats with and 9L gliosarcoma cells inoculated in the brain. Each rat received either: (1) no treatment (control; N = 11), (2) FUS only (N = 9), (3) IV liposomal doxorubicin (DOX only; N = 17), or (4) FUS with concurrent IV injections of liposomal doxorubicin (FUS+DOX; N = 20). Post-treatment by magnetic resonance imaging (MRI) showed that FUS+DOX reduced tumor growth compared with DOX only. Further, we observed a modest but significant increase in median survival time after a single treatment FUS+DOX treatment (p = 0.0007), whereas neither DOX nor FUS had any significant impact on survival on its own. These results suggest that combined ultrasound-mediated BBB disruption may significantly increase the antineoplastic efficacy of liposomal doxorubicin in the brain.

Copyright © 2012 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
A, Experimental set-up for MRI-guided focused ultrasound-induced BBB disruption in rats with implanted 9L gliosarcoma. Pulsed ultrasound was focused in and around the tumor (Frequency: 1.7 MHz, Pressure: 1.2 MPa, Burst length: 10 ms, Repetition frequency: 1 Hz, Duration: 60–120 s; see ref (Treat et al. 2007) for further detail) with simultaneous i.v. administration of Definity microbubble ultrasonic contrast agent. B, Contrast-enhanced T1-weighted magnetic resonance images of the rat brain before (left) and after (right) ultrasound-induced BBB disruption around the tumor showed increased penetration of MR contrast agent through the BBB in the targeted area after sonication.
Fig. 2
Fig. 2
T2-weighted magnetic resonance images of a rat brain with implanted 9L gliosarcoma (outlined) before and 1, 2, and 3 weeks after treatment with focused ultrasound and i.v. liposomal doxorubicin (FUS+DOX; top row) or treatment with i.v. liposomal doxorubicin (DOX only; bottom row). While the tumor in the rat treated with DOX only continued to grow exponentially (R2 = 0.999) even after treatment, tumor growth in the rat treated with FUS+DOX was visibly slowed in comparison.
Fig. 3
Fig. 3
Average tumor volume doubling time in rats with intracranially implanted 9L gliosarcoma after treatment with one of the following: microbubble-enhanced focused ultrasound (FUS only), i.v. administration of 5.67 mg/kg liposomal doxorubicin (DOX only), or microbubble-enhanced focused ultrasound and i.v. administration of 5.67 mg/kg liposomal doxorubicin (FUS+DOX). Doubling time was calculated from exponential growth time constants determined from least-squares regression analyses. Rats treated with FUS+DOX had longer average tumor volume doubling times (3.7 ± 0.5 days) than any other group.
Fig. 4
Fig. 4
Fraction of survival (Kaplan-Meier plot) of rats with intracranially implanted 9L gliosarcoma after treatment on day 8 with one of preparations listed in Fig. 3. Rats which received a single treatment of FUS+DOX had a 24% greater median survival time than nontreated rats (Log-Rank Χ2 = 11.61; p = 0.0007) and a greater proportion in long-term survivors; the other treatment groups were not significantly different from the control group.
Fig. 5
Fig. 5
H&E-stained sections of rat brains with implanted 9L gliosarcoma 48 h after FUS+DOX treatment: A, Damage to gliosarcoma is noted in the peripheral region of the tumor and in the tissue beyond the tumor boundary (arrow); B, Detail of peripheral region of (A) showing parenchymal vacuolation and damaged tumor cells; C – D, Detail of a similar tumor in a rat treated with DOX only, showing intact tissue at the tumor edge and undamaged infiltrating tumor cells in the tissue beyond the solid tumor (C) and surrounding an intact blood vessel (D) (arrows). Scale bars: (A) 500 µm; (B – D) 50 µm.

References

    1. Aubry JF, Tanter M, Pernot M, Thomas JL, Fink M. Experimental demonstration of noninvasive transskull adaptive focusing based on prior computed tomography scans. J Acoust Soc Am. 2003;113:84–93.
    1. Banerjee S, Bhat MA. Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci. 2007;30:235–258.
    1. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.
    1. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473–1479.
    1. Choi JJ, Pernot M, Small SA, Konofagou EE. Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. Ultrasound Med Biol. 2007;33:95–104.
    1. Clement GT, Hynynen K. A non-invasive method for focusing ultrasound through the human skull. Phys Med Biol. 2002;47:1219–1236.
    1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123.
    1. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol. 1998;44:691–695.
    1. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585–2597.
    1. Fry WJ, Fry FJ. Fundamental neurological research and human neurosurgery using intense ultrasound. IRE Trans Med Electron. 1960;ME-7:166–181.
    1. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem. 2007;101:937–949.
    1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8:541–552.
    1. Heimburger RF. Ultrasound augmentation of central nervous system tumor therapy. Indiana Med. 1985;78:469–476.
    1. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907–911.
    1. Hynynen K, Jolesz FA. Demonstration of potential noninvasive ultrasound brain therapy through an intact skull. Ultrasound Med Biol. 1998;24:275–283.
    1. Hynynen K, McDannold N, Clement G, Jolesz FA, Zadicario E, Killiany R, Moore T, Rosen D. Pre-clinical testing of a phased array ultrasound system for MRI-guided noninvasive surgery of the brain-A primate study. Eur J Radiol. 2006
    1. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage. 2005;24:12–20.
    1. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220:640–646.
    1. Jordao JF, Ayala-Grosso CA, Markham K, Huang Y, Chopra R, McLaurin J, Hynynen K, Aubert I. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS ONE. 2010;5:e10549.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
    1. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006a;103:11719–11723.
    1. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun. 2006b;340:1085–1090.
    1. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803.
    1. Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, Yang HW, Huang CY, Wang JJ, Yen TC, Wei KC. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010;255:415–425.
    1. Martin E, Jeanmonod D, Morel A, Zadicario E, Werner B. High-intensity focused ultrasound for noninvasive functional neurosurgery. Ann Neurol. 2009;66:858–861.
    1. McDannold N, Clement GT, Black P, Jolesz F, Hynynen K. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery. 2010;66:323–332.
    1. McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: Histological findings in rabbits. Ultrasound Med Biol. 2005;31:1527–1537.
    1. Mei J, Cheng Y, Song Y, Yang Y, Wang F, Liu Y, Wang Z. Experimental study on targeted methotrexate delivery to the rabbit brain via magnetic resonance imaging-guided focused ultrasound. J Ultrasound Med. 2009;28:871–880.
    1. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 2002;36:555–558.
    1. Raymond SB, Skoch J, Hynynen K, Bacskai BJ. Multiphoton imaging of ultrasound/Optison mediated cerebrovascular effects in vivo. J Cereb Blood Flow Metab. 2007;27:393–403.
    1. Raymond SB, Treat LH, Dewey JD, McDannold N, Hynynen K, Bacskai BJ. Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS ONE. 2008;3:e2175.
    1. Sheikov N, McDannold N, Jolesz F, Zhang YZ, Tam K, Hynynen K. Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. Ultrasound Med Biol. 2006;32:1399–1409.
    1. Sheikov N, McDannold N, Sharma S, Hynynen K. Effect of Focused Ultrasound Applied With an Ultrasound Contrast Agent on the Tight Junctional Integrity of the Brain Microvascular Endothelium. Ultrasound Med Biol. 2008;34:1093–1104.
    1. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol. 2004;30:979–989.
    1. Stan AC, Casares S, Radu D, Walter GF, Brumeanu TD. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res. 1999;19:941–950.
    1. Sun J, Hynynen K. Focusing of therapeutic ultrasound through a human skull: a numerical study. J Acoust Soc Am. 1998;104:1705–1715.
    1. Surawicz TS, Davis F, Freels S, Laws ER, Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 1998;40:151–160.
    1. Treat LH, McDannold N, Zhang Y, Vykhodtseva N, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 2007;121:901–907.
    1. van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer. 2006;42:582–588.
    1. von Holst H, Knochenhauer E, Blomgren H, Collins VP, Ehn L, Lindquist M, Noren G, Peterson C. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien) 1990;104:13–16.
    1. Voulgaris S, Partheni M, Karamouzis M, Dimopoulos P, Papadakis N, Kalofonos HP. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol. 2002;25:60–64.
    1. Walker MD, Alexander E, Jr, Hunt WE, MacCarty CS, Mahaley MS, Jr, Mealey J, Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333–343.
    1. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1405–1409.
    1. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery. 1995;37:1128–1145.
    1. Zarnitsyn VG, Kamaev PP, Prausnitz MR. Ultrasound-enhanced chemotherapy and gene delivery for glioma cells. Technol Cancer Res Treat. 2007;6:433–442.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere